SERD
Interviews and expert commentary tagged “SERD” — the latest oncology research and clinical practice from the Audio Journal of Oncology.
Audio Journal of Oncology
Peter Schmid MD PhD; ASCO 2026: Giredestrant Beats Standard Endocrine Therapies Irrespective of Menopausal Status in Patients with ER+, HER2- Early Breast Cancer
Giredestrant Beats Standard Endocrine Therapies Irrespective of Menopausal Status in Patients with ER+, HER2- Early Breast Cancer An interview with: Peter Schmid MD PhD, Professor of Cancer Medicine;
5 June 2026
8:30
Audio Journal of Oncology
Aditya Bardia MD MPH; 2025 San Antonio Breast Cancer Symposium: Selective Estrogen Degrader Giredestrant Improves on Standard Endocrine Therapy for Patients with ER-positive, HER2-negative Early Breast Cancer: Phase III lidERA Breast Cancer trial Findings
A seective estrogen degrader out-performed AI’s in ER+ HER- early breast cancer
18 December 2025
7:41